Bottom Fish Stocks (between .10 and$10)

[zenvesting]

POSC I still own it from 2 years ago at $0.07 (it's a tiny position). I didn't buy more recently because I didn't like the fact the financing was done pretty cheap at about $0.024/share. If all the financing is executed it will bring the share count to approximately 150M OS.

But on the possitive side, the company will also be selling 10 systems for $1.3million each, which should give them about $0.11 in revenue/share for these 10 sales. Having an investment from a burgeoning PET service provider is also a big possitive IMO. I'll continue to watch and look for a good entry.

I think the recent volume might possibly be related to this, which is a possitive for the PET industry in general:

KNOXVILLE, Tenn., June 16 /PRNewswire-FirstCall/ -- CTI Molecular Imaging, Inc. (Nasdaq: CTMI), a leading provider of positron emission tomography (PET) equipment, molecular biomarkers and services, commented on yesterday's announcement by the Centers for Medicare and Medicaid Services (CMS) regarding Medicare coverage for the use of PET for early diagnosis of Alzheimer's disease.


CMS has announced a national coverage decision to provide Medicare coverage of PET scans to aid physicians in the early diagnosis of Alzheimer's disease and to help differentiate Alzheimer's from other confounding neurological disorders. The coverage decision would authorize Medicare payment for PET scans when certain criteria are met as outlined in the coverage document. This coverage decision is open to public comment for 30 days, followed by implementation in its final form within the next 60 days. Further information is available at http://www.cms.hhs.gov .


Ronald Nutt, Ph.D., President and Chief Executive Officer, commented on the announcement, "CMS has recognized the significant benefit that PET can provide in the diagnosis of patients suspected of having Alzheimer's disease. PET will provide the opportunity for earlier diagnosis, care and treatment of Alzheimer's patients, while also helping to better manage the overall resources applied to care of patients with Alzheimer's disease and associated disorders. We believe that this coverage decision will help to alleviate the anxiety and uncertainty experienced by Alzheimer's patients and their families."


About CTI Molecular Imaging:


CTI Molecular Imaging, Inc. is a leading supplier of products and services for positron emission tomography (PET), a diagnostic imaging technology used in the detection and treatment of cancer, neurological disorders and cardiac disease. Additional information is available at: www.ctimi.com .


About PET and PET/CT:


PET images the biology of diseases at the molecular level, often before changes are visible by anatomical imaging or, in some cases, before symptoms appear. Diseases are biological processes and it is these processes that PET examines. PET/CT combines the biological examination of patients by PET with CT images of the body's structural detail. PET/CT technology improves the diagnostic accuracy and treatment management of patients by providing surgeons, radiation oncologists and other physicians precise anatomical landmarks associated with the disease condition as determined by PET.


PET's whole-body imaging capability helps physicians improve their ability to detect and determine the location, extent and stage of cancer, neurological disorders and cardiac disease. By improving diagnosis, PET scans aid physicians in selecting better courses of treatment, as well as assessing whether treatment is effective or should be changed. Recent published clinical trials have shown that in a wide array of cancers, the use of PET has caused the treatment to be changed for 15 to 50% of patients, depending on the specific clinical question. In addition, PET and PET/CT provide both the patient and their physician with a degree of certainty that is often unavailable through other imaging methods.



Certain matters discussed in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by words such as "assume," "expect," "anticipate," "intend," "estimate" or similar expressions, and any other statements that necessarily depend on future events. Forward- looking statements involve a number of risks and uncertainties and there can be no assurance that any forward-looking statements will prove to be accurate. Various factors could cause actual results to differ materially from those anticipated in the forward-looking statements.

CTI undertakes no obligation to update or revise any forward-looking statements. Further information regarding risks, uncertainties and other factors that could adversely affect CTI or cause actual results to differ materially from those anticipated in forward-looking statements are included in CTI's Annual Report on Form 10-K for the fiscal year ended September 30, 2003 and Quarterly Report on Form 10-Q for the quarter ended March 31, 2004. SOURCE CTI Molecular Imaging, Inc.